The company have substantially improved its course of a new treatment for ATTR-CM, leveraging Attruby. Initial clinical information reveals significant outcomes for individuals diagnosed with this severe disease. This focus underscores BridgeBio's dedication to addressing unmet healthcare requirements in a heart arena. Attruby: BridgeBio's Novel A